-
公开(公告)号：US5639730A
公开(公告)日：1997-06-17
申请号：US165906
申请日：1993-12-14
申请人： Johann Eibl , Gabriela Hummel , Gerda Redl , Thomas Seelich , Peter Turecek , Gunter Wober
发明人： Johann Eibl , Gabriela Hummel , Gerda Redl , Thomas Seelich , Peter Turecek , Gunter Wober
IPC分类号： A61K38/16 , A61K35/14 , A61K38/00 , A61K38/43 , A61K38/46 , A61K38/48 , A61K47/00 , A61L2/00 , C12N5/00 , C07K14/475 , C12N7/06 , A61L2/16
CPC分类号： A61K35/14 , A61L2/0023 , A61L2/0088 , Y10S530/83
摘要： In a method of producing a virus-safe biological preparation by heating while preserving a least 50% of its biologic activity, a biologially compatible tenside is added to the preparation before heating and heating is carried out in the presence of the same, whereupon the tenside, preferably, is eliminated.
摘要翻译： 在通过加热同时保存其生物活性的至少50％来生产病毒安全的生物制剂的方法中，在加热和加热之前，将生物相容的表面活性剂加入制剂中，然后在其上进行表面活性剂 ，优选地被消除。
-
公开(公告)号：US5733885A
公开(公告)日：1998-03-31
申请号：US678594
申请日：1996-07-15
申请人： Johann Eibl , Gabriela Hummel , Gerda Redl , Thomas Seelich , Peter Turecek , Gunter Wober
发明人： Johann Eibl , Gabriela Hummel , Gerda Redl , Thomas Seelich , Peter Turecek , Gunter Wober
IPC分类号： A61K38/16 , A61K35/14 , A61K38/00 , A61K38/43 , A61K38/46 , A61K38/48 , A61K47/00 , A61L2/00 , C12N5/00 , C07K14/475 , C12N7/06 , A61L2/16
CPC分类号： A61K35/14 , A61L2/0023 , A61L2/0088 , Y10S530/83
摘要： In a method of producing a virus-safe biological preparation by heating while preserving a least 50% of its biologic activity, a biologially compatible tenside is added to the preparation before heating and heating is carried out in the presence of the same, whereupon the tenside, preferably, is eliminated.
摘要翻译： 在通过加热同时保存其生物活性的至少50％来生产病毒安全的生物制剂的方法中，在加热和加热之前，将生物相容的表面活性剂加入到制剂中，然后在其上进行表面活性剂 ，优选地被消除。
-
3.发明授权
公开(公告)号：US6013620A
公开(公告)日：2000-01-11
申请号：US926845
申请日：1997-09-11
申请人： Peter Turecek , Hans-Peter Schwarz , Gerda Redl
发明人： Peter Turecek , Hans-Peter Schwarz , Gerda Redl
IPC分类号： A61K38/04 , A61K38/43 , A61K38/46 , A61K38/48 , A61P7/02 , C12N9/64 , A61K35/14 , A61K38/16 , C07K14/745
CPC分类号： C12N9/6437 , A61K38/4846 , C12N9/647 , C12Y304/21021 , Y10S514/834
摘要： The invention relates to a pharmaceutical composition for the treatment of patients with blood coagulation diseases which are caused by coagulation factor deficiency and/or inhibitors of coagulation factors, whereby the composition as a FEIB-activity and is characterized in that it has Factor VIIa and at least one further active ingredient and the activity of at least 10 Factor VIIa units per unit FEIBA. Additionally, the invention comprises a method for the production of the pharmaceutical preparation and its use.
摘要翻译： 本发明涉及一种用于治疗由凝血因子缺乏引起的凝血疾病患者和/或凝血因子抑制剂的药物组合物，其中组合物作为FEIB活性，其特征在于其具有因子VIIa和 至少一种其他活性成分和至少10个因子VIIa单位每单位FEIBA的活性。 此外，本发明包括制备药物制剂及其用途的方法。
-
4.发明授权
公开(公告)号：US5891843A
公开(公告)日：1999-04-06
申请号：US701755
申请日：1996-08-22
申请人： Peter Turecek , Hans-Peter Schwarz , Gerda Redl
发明人： Peter Turecek , Hans-Peter Schwarz , Gerda Redl
IPC分类号： A61K38/04 , A61K38/43 , A61K38/46 , A61K38/48 , A61P7/02 , C12N9/64 , A01N37/18 , A61K35/14 , A61K38/00 , C07K1/00
CPC分类号： C12N9/6437 , A61K38/4846 , C12N9/647 , C12Y304/21021 , Y10S514/834
摘要： The invention relates to a pharmaceutical composition for the treatment of patients with blood coagulation diseases which are caused by coagulation factor deficiency and/or inhibitors of coagulation factors, whereby the composition has a FEIB-activity and is characterized in that it has Factor VIIa and at least one further active ingredient and the activity of at least 10 Factor VIIa units per unit FEIBA. Additionally, the invention comprises a method for the production of the pharmaceutical preparation and its use.
摘要翻译： 本发明涉及一种用于治疗由凝血因子缺乏引起的凝血疾病患者和/或凝血因子抑制剂的药物组合物，其中该组合物具有FEIB活性，其特征在于其具有因子VIIa和 至少一种其他活性成分和至少10个因子VIIa单位每单位FEIBA的活性。 此外，本发明包括制备药物制剂及其用途的方法。
-
公开(公告)号：US5866122A
公开(公告)日：1999-02-02
申请号：US821763
申请日：1997-03-20
申请人： Peter Turecek , Hans-Peter Schwarz , Johann Eibl
发明人： Peter Turecek , Hans-Peter Schwarz , Johann Eibl
IPC分类号： G01N33/86 , A61K31/435 , A61K31/60 , A61K38/00 , A61K38/36 , A61K38/43 , A61K38/48 , A61K38/55 , A61K38/57 , A61K45/00 , A61K47/48 , A61P3/14 , A61P7/02 , A61P7/04 , A61P39/02 , C07K1/18 , C07K1/20 , C07K1/36 , C07K14/745 , C12N9/64 , C12N9/74
CPC分类号： C12N9/6432 , A61K38/4833 , A61K38/4846 , A61K38/57 , C07K1/18 , C07K1/20 , C07K1/36 , C07K14/745 , C12N9/6429 , C12N9/647 , C12Y304/21005 , C12Y304/21006 , Y10S514/822
摘要： There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.
-
公开(公告)号：US5804159A
公开(公告)日：1998-09-08
申请号：US663031
申请日：1996-06-07
申请人： Johann Eibl , Peter Turecek , Hans Peter Schwarz
发明人： Johann Eibl , Peter Turecek , Hans Peter Schwarz
摘要： There is disclosed an anti-plasma antibody preparation for treatment of a mammal, which preparation is capable of directly or indirectly inhibiting and/or eliminating several blood factors, a method of producing such a preparation and a method of evaluating substances for treating clotting disorders by using said anti-plasma antibody preparation. There is further disclosed a method of determining the bleeding characteristics of a mammal.
摘要翻译： 公开了一种用于治疗哺乳动物的抗血浆抗体制剂，该制剂能够直接或间接地抑制和/或消除多种血液因子，制备这种制剂的方法和评估用于治疗凝血障碍的物质的方法通过 使用所述抗血浆抗体制剂。 还公开了确定哺乳动物的出血特征的方法。
-
公开(公告)号：US5410022A
公开(公告)日：1995-04-25
申请号：US49585
申请日：1993-04-20
申请人： Johann Eibl , Friedrich Elsinger , Herbert Gritsch , Yendra Linnau , Otto Schwarz , Peter Turecek , Gunther Wober
发明人： Johann Eibl , Friedrich Elsinger , Herbert Gritsch , Yendra Linnau , Otto Schwarz , Peter Turecek , Gunther Wober
IPC分类号： A61K38/43 , A61K38/00 , A61K38/37 , A61L2/04 , A61L2/16 , A61L2/18 , A61P7/04 , C07K1/14 , C07K1/16 , C07K14/435 , C07K14/745 , C07K14/755 , C12N9/74 , C07K3/20 , C07K15/06
CPC分类号： C07K14/755 , A61K38/00 , Y10S530/83 , Y10S530/831
摘要： The invention relates to a method of producing virus-safe highly purified factor VIII. The method includes a combination of the following measures:a) chromatographic purification of a factor VIII-containing fraction,b) tenside treatment of factor VIII in an aqueous solution at a tenside/protein ratio of from 1:1 to 1000:1, andc) heat treatment of the factor VIII preparation in the solid state.
摘要翻译： 本发明涉及一种生产病毒安全高度纯化因子VIII的方法。 该方法包括以下措施的组合：a）含有因子VIII的级分的色谱纯化，b）在表面活性剂/蛋白质比例为1:1至1000:1的水溶液中进行因子VIII的表面活性剂处理，以及 c）在固体状态下热处理VIII因子制剂。
-
公开(公告)号：US6103693A
公开(公告)日：2000-08-15
申请号：US898130
申请日：1997-07-22
申请人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
发明人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K38/43 , A61P7/04 , C07K1/18 , C07K1/22 , C07K14/47 , C07K14/755 , C12P21/00 , A61K38/17 , C07K14/745
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity.
摘要翻译： 本发明涉及一种用于分离高纯度血管性血友病因子的方法，其中重组血管性血友病因子（rvWF）通过阴离子交换色谱在季氨基型阴离子交换剂上在包含缓冲物质和任选盐的缓冲溶液中进行色谱纯化。 缓冲溶液优选不含稳定剂，氨基酸和其它添加剂。 根据该方法，可以获得高纯度的重组vWF，其不含血浆蛋白质，特别是不含因子VIII，且具有生理活性。 此外，本发明涉及含有rvWF的药物制剂，其由具有高结构完整性的多聚体组成。
-
公开(公告)号：US5880265A
公开(公告)日：1999-03-09
申请号：US898129
申请日：1997-07-22
申请人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
发明人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K38/43 , A61P7/04 , C07K1/18 , C07K1/22 , C07K14/47 , C07K14/755 , C12P21/00
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity.
-
公开(公告)号：US5698677A
公开(公告)日：1997-12-16
申请号：US435128
申请日：1995-05-05
IPC分类号： A61K9/127 , A61K9/14 , A61K38/43 , A61K38/48 , A61K38/55 , A61P7/02 , C12N9/64 , C12N9/96 , A61K35/14
CPC分类号： C12N9/96 , A61K38/4846 , A61K38/4866 , A61K9/127 , C12N9/6424 , C12N9/647 , C12Y304/21006 , C12Y304/21021 , C12Y304/21069
摘要： The invention relates to a stable preparation which comprises a protein that is bound in and/or on lipid vesicles and that was treated for the inactivation of potentially present viruses. Further, the invention relates to methods for the production of a stable preparation for the treatment of blood coagulation disorders, wherein a protein is bound in and/or on lipid vesicles, and the method comprises a step in which the protein lipid complex is subjected to a treatment for the inactivation of potentially present viruses.
摘要翻译： 本发明涉及一种稳定的制剂，其包含结合于脂质囊泡中和/或脂质囊泡上的蛋白质，并且被处理用于灭活潜在的存在的病毒。 此外，本发明涉及生产用于治疗凝血障碍的稳定制剂的方法，其中蛋白质与脂质囊泡中和/或结合，该方法包括将蛋白质脂质复合物经受 用于灭活潜在存在的病毒的治疗。
-
-
-
-
-
-
-
-
-
搜索结果
149 条记录 (耗时 0.025 秒)
